

To the Press:

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

16 August 2011

Today Exiqon announces the first Center of Excellence in North America - Oncogenomics Core Facility (OCF) at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine

Exiqon A/S (NASDAQ OMX: EXQ.CO), a leading supplier of high-value gene expression analysis products, today announced the appointment of a Center of Excellence as part of its new certified service provider program. The Center of Excellence program is introduced in response to an increased demand for Exiqon's LNA™ (Locked Nucleic Acid) products and services.

The Oncogenomics Core Facility (OCF) at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine will offer real-time PCR services based on the Exiqon miRCURY LNA™ Universal RT microRNA PCR product line.

LNA™-based microRNA profiling holds great promise as a non-invasive way to discover important new biomarkers for a wide range of diseases and biological processes. The extreme sensitivity obtained by inclusion of LNA™ in the PCR primers enables the use of non-invasive samples like serum and plasma where the quantity of RNA is extremely low.

"The Oncogenomics Core Facility has had great success over the last several months using the Exiqon LNA qPCR platform and we are excited to be a Center of Excellence", said Toumy Guettouche, Ph.D., Core Director.

"We are pleased to announce the first Center of Excellence in North America", said Henrik M Pfundheller, Ph.D., SVP Sales & Marketing and added: "The demand for profiling microRNAs from body fluids such as serum/plasma and urine is increasing at a fast rate and we are therefore happy to have the Oncogenomics Core Facility as part of our program".

Exiqon plans to announce additional Centers of Excellence in the upcoming months.

Additional information:

Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

Henrik M. Pfundheller, Senior Vice President Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)

See the full press release in the attached PDF or at www.exiqon.com/investor/portal.

About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells and bodyfluids. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to target new medicines based on miRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.